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Abstract 
Polymer based dosages form the mainstay of drug delivery systems either as simple matrix 
carrier materials or active release behaviour modulating agents. In addition, several 
techniques have been developed further to deliver novel polymeric structures. One such 
method is electrospinning (ES); a maturing process which is operational at the ambient 
environment and enables drug loading (in molecularly dispersed form) directly into a fibrous 
polymer matrix system. Since there is an impending need to address healthcare challenges 
arising from an increase in the aging population (requiring enhanced treatments), the ES 
method was used to develop fibrous polymer composite-indomethacin (INDO) films for 
potential use in the buccal region. Films were assessed for their inter-facial behaviour at bio-
interfaces (in-vitro and ex-vivo). Polymeric excipients possessing an established profile for 
commercial dosage form development were selected. Fibrous films (all fibre components 
<400nm) were characterised using DSC, TGA, FTIR, Raman and XRD. DSC and XRD 
demonstrated INDO change from crystalline to amorphous state. FTIR and Raman data 
suggest INDO, PVP and co-polymers (Methocel ™ E5, Methocel ™ E15 and Tween® 80) 
were integrated in stable fashion into filamentous structures via ES.Variable INDO release 
behaviour from several matrices was observed suggesting a potential route to tailor drug 
release based on polymeric excipient use and ratio. Furthermore, permeation studies using a 
porcine buccal model demonstrated sustained permeation once dosages are attached to the 
buccal mucosa.  The insoluble nature of cellulose excipients were used to promote sustained 
release while the use of Tween
®
80 surfactant was used to enhance permeation of INDO 
through polymer interaction with excised tissue. Finally, histology studies indicate polymer 
excipient selection impacts the bio-interface. In summary, a facile approach to formulate, 
encapsulate and engineer fibrous polymeric buccal films (on demand) is shown. The method 
enables drug dispersion directly within the composite polymeric system, which has a clear 
impact on drug release, in-vitro and ex-vivo bio-interaction. 
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1. Introduction 
Polymer selection for the design and development of drug dosage forms is as important as the 
nominated active pharmaceutical ingredient (API) [1]. Formulation and selective use of 
excipients enable specific chemical and physical properties including manufacturing method, 
dosage stability, packaging, handling and bio-interface interactions. A vast variety of 
polymers, from both synthetic and naturally occurring classes, are used for commercial drug 
dosage manufacturing and optimisation. Selection is often derived on the basis of material 
suitability when considering engineering steps during product development (e.g. including 
particle or fibre engineering [2,3]).  
 
The buccal route for API administration has gained popularity over the last decade due to 
advances in drug discovery (coupled with potential opportunistic therapies) [4,5], on-demand 
dosage form development [6] and also to overcome disadvantages associated with 
conventional oral dosage forms (e.g. difficulty swallowing or tolerating the enteric route) 
[7,8]. Several methods to develop or formulate buccal drug delivery systems have been 
explored through innovative developments in films, patches, tablets and even capsules [9]. 
Rapid drug absorption (from various dosage form types e.g. pill or film) has been shown in 
the buccal cavity, in addition to greater patient compliance compared with other oral 
transmucosal administration routes [10]. Furthermore, greater volume of vascularised tissue 
and blood vessels at this location indicate potential entry into systematic circulation [11], 
possibly through the jugular vein [7,10,12]. Avoiding drug hydrolysis (often encountered in 
the gastrointestinal tract), enzymatic and acidic action, as well as bypassing first-pass 
metabolism are all drivers for the development of buccal drug delivery systems [10]. In terms 
of interactions, a characterise feature of the buccal mucosa is fast cellular recovery suggesting 
minimal damage to the administration site upon application [10,13-15]. The anatomical and 
physiological property of the buccal region leads to high drug bioavailability and fast onset of 
action. One such active which has been explored for buccal delivery is nitroglycerin. The API 
has been developed into various sublingual dosage forms  with notable advances in 
ointments, gels, film patches and tablets (e.g. low molecular weight heparins) [16]. 
 
Several engineering methods have been developed to prepare buccal dosage forms which 
include solvent casting [17] and hot melt extrusion [6]. Both methods exhibit advantages and 
limitations during formulation preparation. Electrospinning (ES) is an evolving and maturing 
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engineering method with extensive recent interest in the pharmaceutical arena [8,18,19]. This 
one-step technique has been developed to fabricate fibrous films loaded or co-loaded with 
API (at required quantities in-situ) at the ambient environment [20]. Process aspects (applied 
voltage, flow rate and the distance between tip of processing nozzle to collecting platform) 
and pre-formulated material properties (e.g. viscosity, density, electric conductivity and 
surface tension) are often explored and correlated with processing viability [21-23]. ES has 
numerous sister processes namely, electrospraying [24], EHD printing [25], microbubbling 
[26] and these can be complexed further through the use of two or more processing needles 
[27,28].  
 
Indomethacin (INDO) is a non-steroidal anti-inflammatory drug (hydrophobic) available in 
crystalline form; which is used for the treatment of common illness such as fever, mild to 
moderate pain, swelling and to relieve symptoms of arthritis. INDO inhibits the production of 
prostaglandins which are responsible for inflammation and pain [29,30]. As a model drug, 
enhancement of INDO solubility and dissolution at the buccal site requires amorphisation. 
This is crucial and enhances drug bioavailability as its increases molecular mobility when 
compared with the crystalline form [31]. Numerous studies have focused on the development 
of thin film platforms and the vast majority of these have utilised in-vitro or ex-vivo studies 
for evaluation, although greater bio-interface evaluation is needed. Furthermore, assessment 
using various models (ex-vivo and in-vitro) and how they correlate is valuable.  
 
In the present work, amorphous fibrous INDO films were prepared using 
Polyvinylpyrolidone (PVP), Methocel ™ (E5) premium, Methocel ™ (E15) and Tween® 80 
via single step ES. Films were characterised for their size and their components (presence and 
stability) using spectral techniques.  Drug loading and encapsulation efficiency of the process 
was determined. INDO state was also assessed using XRD analysis and the release behaviour 
of the active was explored in vitro (PBS), while permeation was evaluated using an ex-vivo 
(porcine) model. PBS spreading behaviour on engineered polymer films was evaluated using 
surface contact angle measurements. Finally, buccal mucosa histology (porcine) was 
performed to assess film bio-interface tolerance. 
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Materials and Methods 
Materials 
Indomethacin (INDO), polyvinylpyrrolidone, PVP, (high molecular weight 1.3 x 10
6
 g/mol) 
and phosphate buffer saline were purchased from Sigma-Aldrich (Gillingham, UK). Ethanol 
(HPLC grade) was obtained from Fisher Scientific (Loughborough, UK).Methocel ™ (E5) 
premium, Methocel ™ (E15) and Tween® 80 were purchased from DOW Chemical 
Company-UK.  
 
Solution preparation 
The compositions of all formulations used in this study are listed in Table 1. 75 mL of 
individual polymeric solutions (sufficient for preliminary rheological assessment and film 
preparation) were prepared using ethanol and distilled water (80:20 ratio, respectively) as the 
vehicle. PVP (5% w/w) was dissolved in the vehicle using mechanical stirring (Jenway, 
Staffordshire, UK) for 30 minutes at ambient conditions (24 
o
C). A known quantity of 
selected co-polymer and INDO (5% w/w of PVP) were added to each formulation under 
mechanical stirring until complete dissolution. Several studies have used similar drug loading 
concentrations for fibrous or electrospun materials [32,33]. Paraffin film was used to seal the 
solutions to prevent solvent evaporation. Finally, two additional solutions were prepared by 
adding Tween
®
 80 to (5% w/w of PVP) existing formulations. 
 
Preparation of electrospun fibres and films 
Polymeric solution formulations were infused into an electrically conducting capillary needle 
(possessing inner and outlet diameters of 0.3 and 0.5 cm, respectively) at a rate of 20µL/min. 
Infusion was controlled using a Harvard Apparatus 11-Elite syringe pump (Harvard 
Apparatus, Edenbridge, UK). An electric field (15 ± 2 kV) was supplied via a high voltage 
power supply (Glassman High Voltage, Inc., High Bridge, New Jersey). Glass slides 
(Microscope Slide, WWR, Leicester, UK) were neatly layered with silicon coated paper (to 
ease film removal) and placed 15 cm beneath the needle outlet. Once collected, films were 
then stored in a petri dish. The ES set-up is shown in Figure 1a with the ES needle head 
shown in Figure 1b. During most electrohydrodynamic (EHDA) experimentations various 
liquid atomization modes are observed from dripping (Figure 1c), stable (Figure 1d) to 
multi-jet (Figure 1e) [34,35,36]. The stable jetting mode was determined for each 
formulation and was used to fabricate fibrous films, which were subsequently cut down to a 
suitable size (Figure 1f). 
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Microscopic imaging and size distribution 
Scanning electron microscopy (SEM) was performed using a SEM Carl Zeiss EVO
®
 HD15 
(Carl, Zeiss, Oberkochen, Germany). Fibres were mounted onto the sample holder 
(aluminium stub) using double sided tape. To prevent any overcharging, samples were 
covered with a thin film of gold by sputter coating (S150B, Edwards, Crawley, West Sussex, 
UK). Micrographs were examined and fibre diameters were analysed via SEM program 
Image Tool. The mean fibre diameter distribution and range was determined using 150 
random measurements from each sample (assumed to be representative fibre morphology).  
  
X-ray diffraction studies (XRD) 
Sample crystallinity was evaluated with XRD analysis performed on a BrukerD8-Advance 
diffractometer, operating at 40 kV and 40 mA, using Cu Ka1, at a scanning rate of 0.35 
sec/step. Spectra were collected in the 20 angle from 10-50˚. 
 
Differential scanning calorimetry (DSC) 
DSC analysis was performed using a PerkinElmer Jade DSC differential scanning calorimeter 
(PerkinElmer Ltd., Shelton, CT, USA). Samples (3.5 - 4.2 mg) were placed into an 
aluminium pan (Perkin Elmer) and sealed. Samples were heated from 20 to 200 °C at a 
heating rate of 10°C/min under a nitrogen purge of 70 mL/min.  
 
Thermogravimetric analysis (TGA) 
Thermal behaviour of prepared fibres was analysed using a thermal gravimetric analyser 
TGA (Perkin Elmer Pyris 1 TGA). Each sample was placed in an aluminium pan (TGA, 
Perkin Elmer), weighted (7-10 mg) and heated at a temperature range of 20 to 800°C in a 
nitrogen atmosphere, using heating rate of 10 °C/min.  
 
Fourier Transform infra-red spectroscopy (FTIR) 
The chemical structure of raw materials and prepared fibres was analysed using a Fourier 
Transform Infrared spectrophotometer (FTIR Platinum-ATR fitted with Bruker Alpha Opus 
27 FT-IR). Infrared spectra were recorded in the range 4000 - 400 cm
−1
, obtained using an 
average 30 scans at a resolution of 4 cm
-1 
for each sample.  
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Raman spectroscopy 
Raman spectra were obtained using a FORAM
®
 Raman spectrometer (Foster & Freeman Ltd) 
equipped with a 785 nm laser; accumulating 30 scans at 4 cm
-1 
resolution. Raman spectra 
were collected between 3300 and 100 cm
-1
.  
 
Contact angle measurements 
Phosphate buffer (PBS, pH 6.8) contact angles on fibrous films were measured using “Theta 
light” (Biolin Scientific Attension, Stockholm, Sweden) contact angle measuring equipment. 
Formulations were electrospun onto glass slides for ~ 30 mins and then placed on the testing 
plate. Thereafter, PBS was micro-pipetted onto the films surface. Dynamic contact angles 
were assessed using a video monitor. Each sample was measured three times. 
 
PBS-Film contact time behavior 
Selected film formulations were electropsun directly onto glass slides using parameters 
determined during engineering.  Glass coated slides were then immersed into PBS solution 
for known time intervals and removed. Subsequently, all residual PBS was rapidly dripped 
off from the substrate (through tilting mechanism) and films were allowed to dry for 48 h. 
Samples were then analyzed using SEM for changes to fibre structure, integrity and potential 
precipitation effects. 
 
Drug loading capacity 
Precisely weighted amount (1 mg) of all samples was dissolved in 3 mL of ethanol in capped 
glass vials under magnetic stirring for 15 min to ensure complete dissolution. The resulting 
solutions were centrifuged at 4,500 rpm for 15 min, and quantification of INDO was 
performed on the resulting supernatants using UV-Vis analysis at 320nm (UV-Vis 
spectrophotometer, Shimadzu, UVmini-1240). Experiments were run in triplicate. Drug 
content was calculated according to the following equation [37]. 
 
Drug content (%
W
W 
) = 100 × 
Wdrug
Wdrug loaded fibre
Equation 1 
In vitro release studies 
Release studies were conducted in capped glass vials in an agitating water bath at 37 
o 
C. 5 
mg of each sample was sunk to the bottom of individual vials filled with 20 mL of PBS 
buffer solution pH 6.8. At predetermined time intervals, a 1 mL sample was withdrawn and 
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replaced with an equal volume of fresh and preheated test medium(37 
o
C) buffer solution. 
Samples were centrifuged at 2.500 rpm for 15 min, and the supernatants were analyzed with 
UV-Vis at 320 nm. All experiments were repeated four times. The calibration curve of INDO 
in PBS pH 6.8 showed good linearity (r
2
 = 0.999). INDO release kinetics was examined using 
the Higuchi model (this model was chosen as related studies indicate diffusive mechanisms 
for drug encapsulated within filamentous matrices [38, 39]) via Equation 2:  
 
Q=KHt
1/2                    
Equation 2 
where Q is the amount of drug released in time t and KH is the Higuchi dissolution constant. 
 
Ex-vivo buccal permeation 
Porcine mucosal specimens (from a local slaughterhouse in Thessaloniki) were obtained from 
tissue removed from the inner cheek (buccal area) of freshly slaughtered pigs. After 
sampling, all specimens transferred to laboratory in ice-cold buffer (PBS) within 1 h. 
Specimens were surgically treated to remove excesses of connective and adipose tissue until 
slides 700 ±100 μm. 
 
Appropriate sections of mucosa were mounted in vertical Franz type diffusion cells with a 
diffusion area of 4.9cm
2
 and a compartment volume of 15mL. Tissue disks were equilibrated 
for 10 min at 37 
o
C adding simulated plasma (pH 7.4) in the acceptor compartment. In the 
donor compartment was then placed 20mg of each film in 1 mL of buffer solution simulating 
saliva (pH 6.8). The diffusion studies were carried out at 37°C, under stirring. At regular time 
intervals, samples (1 mL) were withdrawn from the acceptor compartment and the sample 
volume taken out was replaced by fresh fluid. Each experiment was carried out for 6 hours 
and results are reported as means ±SD of three different experiments. Selected sample 
preparation stages are shown in Figures 2a (tissue) and b (permeation). 
 
In all experiments, the drug transferred from the donor to the acceptor compartment was 
quantified using an HPLC system consisting of a LC-10 AD VP pump, an auto sampler 
model SIL-20A HT equipped with a 100 μL loop and a UV-Vis detector model SPD-10A VP 
(SHIMADZU) using a RP-Amide C16, 15cm × 4.6 mm I.D., 5μm particles as column. UV 
detector was set at 264 nm for the detection of indomethacin. The mobile phase consisted of 
acetonitrile: H2O 50:50 (v/v) with the addition of 100μL of CH3COOH per 100mL of mobile 
phase. Flow rate was set at 1 mL/min and the injection volume at 50μL. The HPLC assay was 
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performed at ambient temperature. All solvents were filtered through a 0.45 μm nylon 
membrane and degassed prior to use. The retention time of the column was 9 minutes. The 
calibration curve of the drug showed good linearity (r
2
 = 0.999) in the range of 0.5 -10 ppm. 
 
Analysis of permeation data 
The steady state flux (Jss) across the epithelium were calculated using the following equation 
[40] 
Jss= Q/At (μg/cm
2
 h
-1
)      Equation 3 
where Q is the cumulative amount of drug penetrating the mucosa (μg), A is the diffusional 
area (cm
2
) and t is the total time of the experiment (h). 
 
The permeability coefficient (P) was then calculated by the relationship [41] 
P = Jss/Cd (cm/h)              Equation 4 
where Cd is the drug concentration in the donor compartment (μg/cm3). 
 
Histological evaluation  
Abnormalities of the mucosal architecture after transport studies were evaluated using 4 μm-
thick sections of each of the formalin-fixed and paraffin-embedded samples stained by 
conventional hematoxylin-eosin. Specimens were analyzed in an Olympus CX31 optical 
microscope and microphotographs were taken via the OLYMPUS analysis getIT software. 
 
Statistical analysis 
Differences in transport studies were evaluated by unpaired t-test. A one-way analysis of 
variance with Dunnett's multiple comparison test was performed by comparing formulations 
against formulation F1. The data were considered significantly different when the p-value 
was less than 0.05. 
 
Results and Discussion 
Fibre morphology and size distribution 
Fibrous membranes were engineered using all INDO (solution) formulations. Stable jetting 
was determined using a preliminary applied voltage vs. infusion rate experimental matrix to 
ensure near uniform fibre engineering. To achieve this stable jetting, several modes are 
encountered which become apparent for various types of media [42, 43] at the nozzle exit. In 
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addition, various jetting modes have been developed based on material properties and needle 
alignment and these have an impact on the end structure [44, 45]. However, stable jetting 
windows were determined for INDO-PVP based formulations and were subsequently used to 
engineer fibrous films. 
Figures 3a-e show surface morphology of various electrospun fibrous membranes with inset 
images displaying membrane width (thickness), obtained using horizontal and plan view 
microscopic analysis. All formulated fibres exhibit a smooth surface; albeit with variable 
diameter distributions. The difference is attributed to the inclusion of additional excipients 
and co-polymer ratios [8]. Figures 3f-g show diameter distributions of 150 randomly selected 
fibres from each electrospun membrane sample. The fibre diameter was noted to increase 
upon the inclusion of co-polymer (compared to PVP-INDO alone, F1). Samples F2 and F3 
display mean fibre diameters of 810 ± 300 and 510 ± 400 nm, respectively. Differences to 
mean fibre diameter, however, were also impacted by type of co-polymer selected. For 
example, membranes prepared using Methocel™ E15, possessed fibres with coarser 
diameters when compared to Methocel™ E5. Membranes comprising ES formulations F2 
and F5 exhibit bell-shape fibre diameter distribution pattern, which is associated with 
enhanced drug (INDO) encapsulation resulting in coarser structures [8,46]. 
X-ray diffraction studies 
XRD patterns of electrospun fibrous films and neat INDO are shown in Figure 4. The X-ray 
diffraction pattern of pristine INDO indicates the active to possess a highly crystalline 
structure as multiple sharp diffraction peaks at (~ 2 theta = 10–38°) and principle peaks at 
11.7, 16.7, 19.5, 21.6 and 21.6 observed [8]. The diffraction spectrum of all electrospun 
fibrous films (F1-F5) show a diffused background pattern with complete disappearance of all 
principle INDO peaks. This suggests INDO is well dispersed in fibrous matrices, yielding an 
amorphous state. The amorphous state provides several benefits, including accelerated drug 
release and enhanced drug solubility, which are valuable for bioavailability. However, this 
must be correlated with permeation behavior to gauge real benefit.  
Differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) 
Figure 5 shows DSC and TGA thermograms of electrospun INDO formulations. In its 
obtained form, INDO is crystalline and possesses a melting temperature (Tm) of ~164 °C (as 
shown in Figure 5a). This melting peak is no longer observed for electrospun samples, 
11 
 
indicating the drug is dispersed throughout the polymer matrix post ES. Numerous studies 
have made use of the ES technique to engineer PVP fibres from the raw polymer [47, 48, 49].  
In these, a broad endotherm arising at ~90 C has been reported which is also the case in this 
study for all samples prepared using INDO and PVP. The broad endotherm at this value is 
attributed to dehydration which is most likely due to loss of moisture often adsorbed by 
hygroscopic PVP polymer, the rate of which may be enhanced due to the increased surface 
area of fibrous structures. Furthermore, increasing the ES co-polymer formulation content 
provides greater polymeric matrix volume for active spacing and dispersion.  
TGA was utilized to study thermal degradation behavior of fibrous INDO-polymer composite 
films. Figures 5c and d show TGA thermograms of electrospun formulations. In the current 
study, all fibrous films show two degradation steps; the first relates to weight loss in film 
formulation below 100 °C, which is ascribed to evaporation of residual solvent or surface 
adsorbed moisture on fibrous (and porous) samples. The second weight loss step occurs in the 
range 350-500 °C; and is attributed to degradation and decomposition of components 
comprising fibrous formulations such as PVP and other co-polymer excipients. All C-H, C-N, 
C=O and C-C bonds are compromised with temperatures exceeding 300 °C; after which 
complete decomposition of PVP into nitrogen and carbon oxide powders is observed [50]. 
Previous studies indicate similar degradation steps [51]. 
TGA thermogram of PVP-INDO formulation (F1) shows the highest temperature associated 
with the second weight-loss step when compared with all other fibrous formulations, which 
incorporates a co-polymer excipient into the fibrous drug loaded film. INDO is loaded 
directly into filamentous matrices [8] and previous studies report that a shift in the maximum 
temperature (associated weight-loss step) can be used to validate drug entrapment within 
films [51]. The thermal degradation of a composite formulation is also driven by the active 
ingredient (drug) used; as both increase and decrease in the maximum temperature associated 
weight loss have been shown [51].  
Fourier Transform Infrared (FTIR) and Raman spectroscopic analysis 
Raman and FTIR spectroscopy were used to study structure and molecular conformation of 
fibrous films by probing band vibrations [52]. 
Figure 6 displays Raman and FTIR spectra for electrospun films. Figures 6a and b show 
Raman spectra obtained at 3300-300 cm
-1
 range. Several peaks were observed at 2884 cm
− 1
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(ν(C-Η)) and 2220 cm− 1 (ν(C ≅ N)) in addition to a sharp peak at 3080 cm− 1 which is 
ascribed to O-H vibrational stretching of the carboxylic acid group in INDO. All formulations 
(F2-F5) show a new band at 2760–2770 cm− 1 (corresponding to specific co-polymer 
deployed) along with a significant increase in peak intensity at 3072 cm
- 1
 as compared with 
Raman spectra for F1 (PVP-INDO) which could be attributed to increased amorphous INDO 
content. The data suggests active (INDO), base polymer (PVP), co-polymers (Methocel ™ 
E5, Methocel ™ E15) and Tween® 80 (where integrated) incorporate completely into 
filamentous structure by ES. 
Figures 6c and d show FTIR spectra at the wavelength range 4000–400 cm− 1. PVP 
background is observed in all samples and various characteristic peaks for other excipients 
and the active are detected. Observed peaks were amide νC=O at 1600 cm− 1 which is due to 
vibrations arising from INDO’s aromatic ring. In addition, absorption peaks are observed at 
2980 and 1423 cm
-1
 (attributed to C-H vibration of methyl and methylene) [50] and νC=O 
vibration at 1680 cm
− 1 
from PVP polymer (peaks display weaker intensities at ~1661 cm
− 1
) 
due to hydrogen bonding with the active and other co-polymers [53]. Although near identical 
peaks are observed between formulations and pristine samples, a new peak is observed 
between 1087–1113 cm− 1, and is ascribed to carboxylic acid carbonyl stretching within co-
polymer molecules which may arise due to hydrogen bonding or Van der Waals forces.  
Contact angle measurements 
Contact angle measurements were used to assess film hydrophilicity as shown in Figure 7. 
Dynamic PBS contact angles on fabricated films were measured at 0, 2, 4 and 8 seconds. PBS 
contact angle on PVP-INDO fibrous film decreased from 68 to 59◦ over the assessment 
period. Upon the inclusion of co-polymers Methocel ™ (E5) premium (F2) and Methocel ™ 
(E15) (F3), the PBS contact angle changed from 68 to 47
◦
 and from 74 to 47
◦
, respectively. 
This suggests the inclusion of cellulose based co-polymers reduces PBS contact angle over 
time. A significant improvement to PVP-INDO samples wettability was noticed upon the 
inclusion of Tween
®
 80; as the PBS contact angle decreased from 68 to 21
◦
 for F4 and from 
74 to 24
◦
 for F5. Hence, Tween 
®
 80 enhances the hydrophilic property of fibrous films. 
Membrane –medium contact behavior 
To investigate structural change to fibrous components when in contact with test medium; 
pristine PVP fibres, PVP-INDO composite fibres and raw INDO powder was assessed using 
13 
 
interfacing PBS medium. PVP fibres dissolved rapidly even at 1s and fibre integrity was 
compromised indicated by continuous threads transitioning into beaded structures (Figure 
8b), which then merge to form more coarse PVP particles. Inclusion of INDO into fibrous 
PVP matrices (Figure 8c) yield similar structures at the initial stage. When in contact with 
PBS, over designated time period, PVP dissolves leaving discrete PVP components. 
However, an indication of INDO precipitation is suspected (Figure 8c) with reduced PVP 
content; which eludes to the importance of both solubility (dispersion) and permeability. In 
comparison to raw INDO powder (Figure 8a), precipitates forming from rapid solubilisation 
of PVP are much smaller and therefore provide a greater surface area for interaction (i.e. for 
further INDO solubility). 
In vitro release studies 
Table 1 represents drug content in fibrous films which ranged from 2.89 to 4.93% w/w. The 
values are less than the theoretical maxim (5% w/w) incorporated into ES formulations prior 
to processing. This is due to drug precipitation during the ES process or shortly thereafter. 
Moreover, samples prepared using co-polymer Methocel
TM
(E15) reveal greater drug 
encapsulation compared to Methocel
TM 
(E5). 
 
Cumulative release profiles of various INDO formulations are illustrated in Figure 9 (a & b). 
The presence of methyl cellulose results in a decrease in API release rate (formulations F2 & 
F3) compared to the single polymer-drug system (PVP-INDO, F1).Here, sustained release is 
attributed to the non-soluble nature of cellulose based components. However, the sustained 
effect is less well pronounced when Methocel
TM
 (E5) is co-formulated in the film system. In 
this instance, 80 % of drug is released within 2h, whereas when prepared using its congener 
(Methocel
TM
(E15)) only 60 % of active is released. The higher release rate is linked to 
superior swelling behavior of Methocel™ (E5) arising from enhanced hydration rate, 
molecular mass and viscosity compared to Methocel™ (E15) [54] (viscosity of Methocel™ 
(E5) and Methocel™ (E15) is 4-6 and 12-18, respectively [55]). The addition of non-ionic 
surfactant (Tween
®
 80) has little notable effect on INDO release (formulations F4 & F5). 
 
Higuchi kinetic model fitting was applied to in vitro drug release data (from engineered 
fibrous films). Drug release from all formulations showed two distinct release phases; an 
initial burst type release phase followed by a lag period. The Higuchi kinetic model fitting 
was applied to the initial phase. Correlation coefficient (R
2
) and the release rate constant 
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(K) are shown as insets in Figures 9 (a and b). All formulations show high linearity with R
2 
(>0.92).  It can be concluded that the dominating mechanism for INDO release is fickian 
diffusion. However, the release rate is different for each formulation; where F1 possessed the 
greatest K value and F5 possessed the lowest K value. 
 
Transport studies 
The cumulative permeation profiles of tested formulations are shown in Figure 10. 
Comparable cumulative amounts of INDO across buccal epithelium were obtained for 
formulations F1, F2 and F3 (ca. 24μg cm-2 h-1). The highest quantity of INDO transported 
across porcine mucosa was obtained for formulation F4; (48.71μg cm-2 h-1) accordingly (not 
significantly different t-test p>0.05). These values might be explained considering the 
significant improvement of PVP-INDO wettability when Tween
®
 80 was present allowing 
better adhesion of fibrous films to the mucosa. It should be noted that a lag time of 1 h for F4 
and 2 h for all the rest formulations was noticed which is likely to be attributed to the slow 
mucosal adhesion process. 
 
Histological Evaluation  
Light microscopy studies were performed to further assess any histological changes upon 
application of tested formulations on to the surface of porcine buccal epithelium. When 
comparing the normal buccal non-keratinized epithelium (Figure 11A) with the F1 treated 
tissue (Figure 11B), desquamation of superficial keratinocytes and disorganization of 
collagen beneath basal membrane could be identified. In contrast, buccal non-keratinized 
epithelium after 6 h treatment with Methocel™ (E5) (F2) and Methocel™ (E15) (F3) 
revealed mild desquamation of superficial epithelium (Figure 11 C & D). F2 formulational 
also showed mild disorganization at basal membrane. The most pronounced effect to 
epithelial alterations was observed for the F4 and F5 formulations. In case of Methocel
TM
 
(E5)/Tween
®
 80 (F4) was observed strong vacuolation of epithelial cells, and of Methocel
TM
 
(E15)/Tween
® 
80 (F5) less vacuolation but with intense superficial desquamation. The 
histological findings show the effect of both types of Methocel
TM
 and Tween
®
 80, further 
corroborating the ex vivo data. 
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Conclusions 
The results show that various formulations of fibrous buccal patches containing INDO (as a 
model drug) can be easily engineered by means of the ES method into the amourphous state. 
The addition of Tween
®
 80 to PVP-INDO formulations significantly improved their 
wettability. Patches containing methocel and Tween
®
 80 were found to exhibit the highest 
permeation of INDO across porcine mucosa without significantly affecting the ultrastructure 
of the oral mucosa. 
Table and Figure Captions 
Tables 
Table 1. Formulated film sample compositions. All prepared using PVP (5 w/v %) and INDO 
(5 w/w % of PVP). Other excipients added in quantities shown as a function of w/w % of 
PVP. Calculated drug content within engineered samples. 
Figures 
Figure 1. Experimental set-up for electrspinning of fibrous films; (a) Apparatus showing 
position of nozzle (b) processing nozzle with no formulation flow (c) stable jetting at low 
voltage (d) stable jetting at increased voltage with change to cone-jet morhology (e) multi-
jets arising from unstable processing.[scale bar = 3mm] (f) digital image of prepared films 
[scale bar = 2cm]. 
Figure 2.Preparation of porcine ex-vivo permeation model and incorporation into diffusion 
cell showing (a) tissue preparation and (b) permeation assessment using Franz cells. 
Figure 3.Electron micrographs of film samples and side view as insets for formulations (F): 
(A) F1 (B) F2 (C) F3 (D) F4 (E) F5. (F) and (G) show fibre diameter distributions of various 
spun films 
Figure 4. X-ray diffractograms of (A) Pure Indomethacin (B) Methodcel E5 and (C) 
Methocel E15 samples. 
Figure 5. Thermal analysis of engineered films and selected excipients using (A & B) 
Differential scanning calorimetry and (C & D) Thermal gravimetric analysis 
16 
 
Figure 6. Spectroscopic analysis of engineered films and selected excipients using (A & B) 
Raman and (C & D) Fourier transform infra-red 
Figure 7.PBS contact angle data on fibrous films. (A) Camera imaging sequences showing 
changes to droplet behaviour at film interface over time (B) % change to contact angle from 
initial contact and (C) change to contact angle over time. 
 
Figure 8. Electron micrographs showing PBS-film contact behaviour through changes to 
fibre structure over selected time intervals.  
Figure 9.Release profiles of (A). F1, F2, F4, (B). F1, F3, F5 formulations in buffer pH=6.8. 
(mean ± S.D., n=3). 
Figure 10.Cumulative permeated amount of indomethacin across porcine mucosa from 
various film samples. 
Figure 11.Light micrographs of A. porcine buccal mucosa with non-keratinized epithelium 
(intact), B. F1 formulation, C. F2 formulation, D. F3 formulation, E. F4 formulation and F. 
F5 formulation (Magnification x100). 
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Tables and Figures 
Tables 
Table 1 
FORMULATION 
ID 
COMPOSITION DRUG CONTENT 
(W/W %)* 
F1 PVP/INDO 4.43 ± 0.21 
F2 PVP/INDO/Methocel ™ (E5) 5% 2.89 ± 0.85 
F3 PVP/INDO/Methocel ™ (E15) 5% 4.10 ± 0.02 
F4 PVP/INDO/Methocel™ (E5) 5% / Tween
®
 80 3.35 ± 0.49 
F5 PVP/INDO/Methocel™(E15)5% / Tween
®
 80 3.75 ± 0.39 
 
*INDO content in all formulation is 5% w/w of PVP prior to processing. Drug content is based on the 
measured value after films have been formed. 
*Tween
®
 80 content in F4 and F5 is 5% w/w of PVP 
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Form. R
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 K
  
F1 0.94 21.6 
F3 0.93 9.76 
F5 0.92 6.91 
 
Form. R
2 
 K
  
F1 0.94 21.6 
F2 0.94 11.41 
F4 0.95 10.66 
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